uu.seUppsala University Publications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Everolimus Plus Octreotide Long-Acting Repeatable (LAR) for the Treatment of Advanced Neuroendocrine Tumors (NET) Associated with Carcinoid Syndrome: Updated Overall Survival Results from RADIANT-2 Study
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Medical Sciences.
Show others and affiliations
2014 (English)In: Pancreas, ISSN 0885-3177, E-ISSN 1536-4828, Vol. 43, no 3, 508-509 p.Article in journal, Meeting abstract (Other academic) Published
Place, publisher, year, edition, pages
2014. Vol. 43, no 3, 508-509 p.
National Category
Gastroenterology and Hepatology
Identifiers
URN: urn:nbn:se:uu:diva-228361ISI: 000333166800085OAI: oai:DiVA.org:uu-228361DiVA: diva2:734047
Conference
6th Annual Meeting of the North American NeuroEndocrine Tumor Society, October 4–5, 2013, Charleston, South Carolina
Available from: 2014-07-14 Created: 2014-07-11 Last updated: 2017-12-05Bibliographically approved

Open Access in DiVA

No full text

Authority records BETA

Öberg, Kjell E.

Search in DiVA

By author/editor
Öberg, Kjell E.
By organisation
Department of Medical Sciences
In the same journal
Pancreas
Gastroenterology and Hepatology

Search outside of DiVA

GoogleGoogle Scholar

urn-nbn

Altmetric score

urn-nbn
Total: 350 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf